Thomas Woiwode - Adverum Biotechnologies Director
| ADVM Stock | USD 10.19 0.81 7.36% |
Director
Mr. Thomas Woiwode, Ph.D., is Independent Director of the Company.Dr. Woiwode was with Versant Ventures, a VC firm, since 2002 in various capacities, serving as a Venture Partner since 2011 and a Managing Director since 2014. He has served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, a biopharmaceutical company, from April 2011 until May 2013, when Okairos was sold to GlaxoSmithKline plc. Prior to Okairos, Dr. Woiwode cofounded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotech companies created within Versant. Dr. Woiwode was a research scientist at XenoPort, Inc., a biotechnology company, before joining Versant. Dr. Woiwode serves on the board of directors of CRISPR Therapeutics AG and previously served on the board of directors of Audentes Therapeutics, Inc. He received a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Stanford University since 2016.
| Age | 45 |
| Tenure | 8 years |
| Address | 100 Cardinal Way, Redwood City, CA, United States, 94063 |
| Phone | 650 656 9323 |
| Web | https://adverum.com |
Adverum Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.3214) % which means that it has lost $0.3214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8843) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies' management efficiency ratios could be used to measure how well Adverum Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -0.71. In addition to that, Return On Capital Employed is likely to grow to -0.79. At this time, Adverum Biotechnologies' Total Assets are very stable compared to the past year. As of the 25th of April 2024, Non Currrent Assets Other is likely to grow to about 1.3 M, while Other Current Assets are likely to drop about 4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Will Feest | AN2 Therapeutics | N/A | |
| Shmuel Nir | Galmed Pharmaceuticals | 51 | |
| David McGirr | Rhythm Pharmaceuticals | 63 | |
| Bassil Dahiyat | Kodiak Sciences | 47 | |
| Kerry Clark | AN2 Therapeutics | 63 | |
| John Fowler | Kezar Life Sciences | 52 | |
| Joel Marcus | MeiraGTx Holdings PLC | 70 | |
| Arnold Levine | MeiraGTx Holdings PLC | 78 | |
| Anders Ekblom | Mereo BioPharma Group | 63 | |
| Rajeev Shah | Solid Biosciences LLC | 40 | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| Felix Baker | Kodiak Sciences | 49 | |
| Patrick Machado | Rocket Pharmaceuticals | 53 | |
| Robert Profusek | Kodiak Sciences | 68 | |
| Young Sung | Rezolute | N/A | |
| Gregory Moss | MeiraGTx Holdings PLC | 33 | |
| Lynne Sullivan | Solid Biosciences LLC | 51 | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Jennifer Good | Rhythm Pharmaceuticals | 53 | |
| Jason Dinges | Kezar Life Sciences | 42 | |
| Richard Jones | Mereo BioPharma Group | 50 | |
Management Performance
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.32 |
Adverum Biotechnologies Leadership Team
Elected by the shareholders, the Adverum Biotechnologies' board of directors comprises two types of representatives: Adverum Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adverum. The board's role is to monitor Adverum Biotechnologies' management team and ensure that shareholders' interests are well served. Adverum Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adverum Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Neuman, Interim Chief Medical Officer | ||
| James Scopa, Director | ||
| Romuald Corbau, Chief Officer | ||
| Lawrence Kam, Director | ||
| Patrick Machado, Independent Director | ||
| Michael Steel, Senior Quality | ||
| Thomas Woiwode, Director | ||
| Brigit Riley, Chief Officer | ||
| Anand Reddi, VP Engagement | ||
| Mehdi Gasmi, CTO | ||
| Steven Schwartz, Co-Founder, Director | ||
| Leone Patterson, CFO, Principal Financial Officer | ||
| Paul Wachter, Director | ||
| Mark Blumenkranz, Chairman of the Board, Co-Founder | ||
| Michael Swartzburg, Principal Accounting Officer | ||
| Rekha Hemrajani, Director | ||
| Jennifer Cheng, Vice President General Counsel | ||
| Athena Countouriotis, Senior Vice President Chief Medical Officer | ||
| Aaron Osborne, Chief Medical Officer | ||
| Mitchell Finer, Director | ||
| Thomas Leung, CFO | ||
| Eric Carter, Director | ||
| Amber Salzman, President COO, Director | ||
| Laurent Fischer, CEO President | ||
| Jim Wang, Chief Officer | ||
| Andrew Ramelmeier, Chief Officer | ||
| Kalliopi MD, Senior Development | ||
| Jill Steier, Senior Vice President | ||
| Richard Spivey, Independent Director | ||
| Setareh PharmD, Chief Officer | ||
| John JD, Senior Counsel | ||
| Linda MA, Principal CFO | ||
| Mike Fitzgerald, Vice President of Human Resources | ||
| Mark Lupher, Director | ||
| Dena House, Organizational Resources | ||
| Carlo Russo, Executive Vice President and Chief Medical Officer | ||
| Heikki Jouttijarvi, Senior Operations | ||
| Paul Cleveland, CEO, Director | ||
| Kishor JD, Chief Officer | ||
| Nancy Pecota, Principal Officer | ||
| Samuel Barone, Senior Vice President Clinical Development | ||
| Bill PharmD, Senior Operations | ||
| Carla Fiankan, Senior Affairs | ||
| John McLaughlin, Director |
Adverum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adverum Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (34.38) % | ||||
| Current Valuation | 206.81 M | ||||
| Shares Outstanding | 20.75 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 81.80 % | ||||
| Number Of Shares Shorted | 889.95 K | ||||
| Price To Earning | (2.10) X | ||||
| Price To Book | 2.92 X |
Pair Trading with Adverum Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Adverum Stock
| 0.55 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.54 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.44 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.
The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Adverum Stock analysis
When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.60) | Revenue Per Share 0.357 | Quarterly Revenue Growth (0.70) | Return On Assets (0.32) | Return On Equity (0.88) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.